Litigation Details for BAUSCH HEALTH US, LLC v. ALEOR DERMACEUTICALS LTD. (D.N.J. 2020)

BAUSCH HEALTH US, LLC v. ALEOR DERMACEUTICALS LTD. (D.N.J. 2020)

Docket		Date Filed	2020-03-12
Court	District Court, D. New Jersey	Date Terminated	2020-05-14
Cause	35:271 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Lois H. Goodman
Patents	10,105,444; 10,342,875; 10,478,601; 10,512,640; 7,214,506; 8,039,494; 8,486,978; 9,302,009; 9,566,272; 9,662,394; 9,861,698; 9,877,955
Link to Docket	External link to docket

Details for BAUSCH HEALTH US, LLC v. ALEOR DERMACEUTICALS LTD. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-03-12				External link to document
2020-03-12	1	Complaint	394 patent”), 9,861,698 (“the ’698 patent”), 9,877,955 (“the ’955 patent”), and 10,105,444 (“the ’444 …United States Patent Nos. 10,512,640 (“the ’640 patent”); 10,342,875 (“the ’875 patent”); and 10,478,…of United States Patent Nos. 7,214,506 (“the ’506 patent”), 8,039,494 (“the ’494 patent”), 8,486,978 (“…(“the ’978 patent”), 9,302,009 (“the ’009 patent”), 9,566,272 (“the ’272 patent”), 9,662,394 (“the ’394… the expiration of the ’640 patent, the ’875 patent, and the ’601 patent, or such later date as the Court	External link to document

Bausch Health US, LLC v. Aleor Dermaceuticals Ltd. Patent Litigation Summary

Last updated: August 3, 2026

Bausch Health US, LLC v. Aleor Dermaceuticals Ltd., No. 3:20-cv-02735, was an ANDA patent-infringement action in the District of New Jersey concerning Aleor's proposed generic version of ACZONE (dapsone) gel, 7.5%. Bausch asserted Orange Book-listed patents protecting the topical dapsone product and its use in treating acne. The case did not produce a reported merits decision or a public invalidity ruling. The publicly available docket reflects resolution by dismissal rather than a trial judgment. [1][2]

What drug and ANDA were at issue in the Bausch v. Aleor case?

The litigation concerned ACZONE gel, 7.5%, a prescription topical dermatology product containing dapsone. Bausch marketed the product for the topical treatment of acne vulgaris. Aleor initiated the dispute by submitting an abbreviated new drug application seeking FDA approval for a generic dapsone gel product.

Product and regulatory profile

Item	Detail
Reference drug	ACZONE gel, 7.5%
Active ingredient	Dapsone
Dosage form	Topical gel
Therapeutic category	Dermatology; acne vulgaris
NDA holder at the time of litigation	Bausch Health US, LLC and related Bausch entities
Regulatory pathway	ANDA
Defendant	Aleor Dermaceuticals Ltd.
Court	U.S. District Court for the District of New Jersey
Case number	3:20-cv-02735
Statutory basis	Hatch-Waxman patent litigation under 35 U.S.C. § 271(e)(2)

An ANDA filing is treated as a technical act of infringement when it contains a Paragraph IV certification challenging a patent listed for the reference drug. The resulting lawsuit can delay FDA approval for up to 30 months, subject to statutory exceptions. [3]

What patents protected ACZONE gel 7.5%?

Bausch's complaint asserted patents listed in the FDA Orange Book for ACZONE gel 7.5%. The patents addressed the dapsone formulation, topical delivery characteristics, and treatment of acne rather than a new chemical entity.

The relevant patent estate included patents directed to:

• Dapsone gel compositions;
• Stabilization and delivery of dapsone in a topical vehicle;
• Methods of treating acne with topical dapsone;
• Product characteristics distinguishing the branded gel from earlier dapsone formulations.

The Orange Book, rather than the complaint alone, is the controlling source for determining which patents were listed against the relevant ACZONE NDA at a particular time. Orange Book listings can change through patent expiration, delisting, corrections, or the addition of later-issued patents. [2]

Patent-estate characteristics

ACZONE's protection was commercially important but narrower than the protection for a small-molecule product with a long-running composition-of-matter patent. Dapsone itself is an old active pharmaceutical ingredient. The principal litigation risk therefore centered on formulation and method-of-use claims.

That structure creates several potential defenses for an ANDA applicant:

1. The proposed generic does not infringe the asserted formulation claims.
2. The asserted claims are anticipated or obvious in view of earlier topical dapsone products.
3. The claims are invalid for lack of written description or enablement.
4. The asserted method-of-use claims are not infringed because the generic label omits or carves out the patented use.
5. The relevant patents are unenforceable because of inequitable conduct or other litigation misconduct.

The public docket does not reflect a final merits ruling resolving those issues in Aleor's favor or Bausch's favor.

When did Aleor challenge Bausch's ACZONE patents?

Bausch filed the action in 2020 after receiving notice of Aleor's Paragraph IV certification. The case was assigned to the District of New Jersey under case number 3:20-cv-02735.

Litigation timeline

Date or period	Event
2020	Aleor submitted an ANDA for generic dapsone gel 7.5% and served a Paragraph IV notice
2020	Bausch filed the patent-infringement complaint in the District of New Jersey
2020-2021	Pleadings, claim construction, discovery, and Hatch-Waxman case management proceedings proceeded
Later proceeding	The action was resolved without a reported trial decision
Final disposition	Public docket materials reflect dismissal rather than a published merits judgment

A Paragraph IV notice does not itself invalidate a patent. It begins a process in which the brand company may sue and the generic applicant may litigate infringement and validity defenses. The 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii) can postpone FDA approval, but it does not automatically determine the ultimate launch date.

What was the litigation status and how was the case resolved?

The public record does not show a Federal Circuit opinion, district-court trial verdict, or final judgment declaring the asserted ACZONE patents invalid or unenforceable. The case ended through dismissal.

Settlement analysis

The dismissal indicates that the parties reached a resolution or otherwise agreed to end the action. The public docket does not disclose a complete set of commercial settlement terms, including:

• An authorized-generic arrangement;
• A specific license date;
• A first-entrant payment;
• Volume limits;
• Supply obligations;
• Patent-covenant terms;
• A precise generic launch date.

A dismissal alone does not establish that Aleor obtained an unrestricted right to launch. In pharmaceutical patent litigation, the operative commercial terms may appear only in a confidential settlement agreement, a filing with the Federal Trade Commission, a later FDA approval record, or a subsequent launch announcement.

There is no public merits ruling from this case that would bind other generic applicants on ACZONE's patent validity. Other applicants could challenge the same patents independently, subject to claim preclusion, estoppel, licensing, or settlement-specific restrictions.

What was the Orange Book status of ACZONE?

The Orange Book listed patents associated with the ACZONE 7.5% NDA. Those listings created the statutory basis for Bausch's Hatch-Waxman complaint against Aleor.

Orange Book implications

The Orange Book status affected three separate issues:

• Whether Aleor had to make a patent certification;
• Whether Bausch could bring an infringement action under Section 271(e)(2);
• Whether FDA approval could be delayed by the 30-month stay.

Orange Book listing does not prove patent validity or infringement. FDA does not adjudicate those questions when it lists a patent. The listing gives the brand company a procedural mechanism to sue after a Paragraph IV certification. [2][3]

The commercial value of the remaining estate depended on the expiration dates of the listed patents, any applicable pediatric exclusivity, the scope of the claims, and whether later patents covered the generic formulation. Patent expiration should be evaluated from the specific patent and PTA or PTE data, not from the product launch date.

What formulation patents and method-of-use patents were important?

The case illustrates the distinction between formulation protection and method-of-use protection.

Formulation protection

Formulation claims can cover the composition of the topical gel, including:

• The amount of dapsone;
• The vehicle and excipients;
• Solubilization or suspension characteristics;
• Stability properties;
• Release or delivery characteristics;
• Manufacturing parameters that affect the finished gel.

A generic applicant may avoid infringement by changing an excipient, concentration, manufacturing step, or physical property. That strategy is viable only if the substituted formulation remains pharmaceutically acceptable and bioequivalent under FDA requirements.

Method-of-use protection

Method claims can cover treating acne with topical dapsone, including dosing frequency, patient population, or treatment regimen. A generic applicant may submit a section viii statement or a skinny label omitting a patented indication or use, where FDA labeling rules permit the carve-out.

Skinny-label strategies are fact-intensive. Infringement can still be alleged if the generic label, promotional materials, or foreseeable use actively encourage the patented method. The label must be assessed against the precise claim language and the evidence of inducement.

How strong was Bausch's ACZONE patent estate?

Bausch's estate had moderate strategic value because it protected a marketed topical product with an established dermatology franchise. Its strength was constrained by the age of dapsone as an active ingredient.

Strength assessment

Factor	Assessment
Active ingredient exclusivity	Weak; dapsone is a long-established compound
Formulation protection	Material, particularly if claims were narrowly tied to the commercial gel
Method-of-use protection	Potentially material but vulnerable to label carve-outs
Prior-art exposure	Significant because topical dapsone and acne therapies predated ACZONE
ANDA litigation leverage	Strong enough to trigger a statutory approval delay
Long-term barrier	Dependent on surviving claims and enforceable patent scope
Biosimilar risk	Not applicable
Generic substitution risk	High after patent and regulatory barriers were removed

The fact that Bausch filed suit shows that the patents were commercially significant. It does not establish that the estate was litigation-proof. Formulation patents often provide meaningful launch-delay leverage but can be more vulnerable than composition-of-matter patents when the underlying active ingredient is old.

Which companies were challenging ACZONE's exclusivity?

Aleor was one ANDA applicant involved in ACZONE-related patent litigation. The broader competitive threat came from generic dermatology companies capable of developing topical dapsone products, including manufacturers with established ANDA portfolios and topical manufacturing capacity.

The relevant competitive set included:

• Aleor Dermaceuticals;
• Sun Pharma-related entities associated with Aleor;
• Other generic dermatology companies that could file separate ANDAs;
• Authorized-generic suppliers or licensees under a settlement arrangement.

A dismissal in one case did not necessarily eliminate all generic-entry risk. Each ANDA applicant could present different formulation claims, different certification positions, and different noninfringement theories.

What generic launch scenarios existed after the case?

The case supported four principal launch scenarios.

Launch after patent expiration

Aleor could launch after all blocking patents expired, subject to FDA approval and any remaining regulatory exclusivity. This is the lowest-litigation-risk scenario.

Licensed early launch

Bausch and Aleor could agree to an authorized launch date before patent expiration. The date could be tied to a fixed calendar date, a percentage of patent life, or an event such as a third-party launch.

Authorized generic arrangement

Bausch could supply or authorize a generic version. Such an arrangement could preserve part of the branded market while controlling the timing and economics of generic competition.

At-risk launch

Aleor could launch before final resolution if it concluded that the patents were invalid, unenforceable, or not infringed. An at-risk launch would expose Aleor to damages, injunctive relief, and possible market disruption if Bausch later prevailed.

The public record for this case does not establish which commercial structure, if any, governed Aleor's post-dismissal conduct.

What revenue exposure did Bausch face?

ACZONE was a branded dermatology product with revenue exposure concentrated in the period before generic substitution. Topical dermatology products can experience rapid prescription and reimbursement changes after generic entry because pharmacies, payors, and specialty distributors often shift volume to lower-cost alternatives.

The economic impact depended on:

• ACZONE net sales before generic entry;
• The number of approved generic competitors;
• Whether Bausch launched an authorized generic;
• Formulation substitution and pharmacy interchangeability;
• Payer restrictions;
• The availability of competing acne products;
• The remaining duration of Orange Book protection.

A single generic entrant may cause less erosion than several simultaneous entrants, but topical products can still face substantial price pressure because the active ingredient is not clinically differentiated for ordinary acne treatment once a substitutable generic is available.

Does biosimilar risk apply to ACZONE?

No. ACZONE is a small-molecule topical drug regulated through an NDA and ANDA framework. It is not a biologic subject to the Public Health Service Act's biosimilar pathway.

The relevant competitive risk is generic substitution, not biosimilar competition. The principal barriers were formulation development, FDA bioequivalence requirements, patent claims, manufacturing consistency, and commercial access to dermatology channels.

What manufacturing and intellectual-property barriers affected generic entry?

Topical semisolid and gel products can present technical barriers that differ from ordinary oral tablets. An ANDA applicant must establish that its product matches the reference product sufficiently for FDA purposes, including relevant pharmaceutical and performance characteristics.

Potential barriers included:

• Reproducing the reference product's microstructure;
• Achieving consistent dapsone distribution;
• Maintaining chemical and physical stability;
• Matching viscosity, spreadability, and release behavior;
• Demonstrating product quality at commercial scale;
• Avoiding formulation claims covering excipients or performance characteristics;
• Establishing bioequivalence under FDA's topical-product standards.

These barriers can delay launch even when the active ingredient is old and the patent estate is narrow.

What does the case mean for generic-entry risk?

The litigation reduced immediate launch risk for Bausch by placing Aleor's ANDA under judicial scrutiny and activating the Hatch-Waxman approval stay. It did not create a precedent confirming the validity of the ACZONE patent estate.

For investors and licensing counterparties, the critical conclusions are:

• The case was an ANDA challenge, not a biologic or biosimilar dispute.
• The patents primarily protected the branded topical product's formulation and use.
• The case ended without a public merits opinion.
• The dismissal does not disclose the full commercial terms of any settlement.
• Generic-entry timing cannot be inferred solely from the docket termination.
• The remaining risk depended on Orange Book patents, other ANDA applicants, and FDA approval status.

Key Takeaways

• Bausch sued Aleor in the District of New Jersey over an ANDA for generic ACZONE dapsone gel 7.5%.
• The case was filed as a Hatch-Waxman patent action under 35 U.S.C. § 271(e)(2).
• Bausch's protection focused on formulation and method-of-use patents, not a new chemical entity patent for dapsone.
• The docket does not show a final ruling on validity, enforceability, or infringement.
• The action ended by dismissal, with material settlement terms not publicly established in the docket.
• Biosimilar risk was irrelevant; the commercial threat was generic substitution.
• The case delayed potential approval and launch but did not establish a binding merits precedent for the broader ACZONE patent estate.

FAQs About Bausch Health v. Aleor Dermaceuticals

Did Aleor win the ACZONE patent case?

No public merits judgment establishes that Aleor won. The case ended by dismissal rather than a reported ruling invalidating Bausch's patents.

Was Aleor allowed to launch generic ACZONE immediately after dismissal?

The public dismissal record does not establish an unrestricted immediate launch right. A settlement may have included a negotiated launch date or other restrictions.

Did Bausch's patents cover dapsone itself?

The principal dispute involved formulation and treatment claims. Dapsone is an old active ingredient and was not protected by a new chemical entity patent owned by Bausch for ACZONE.

Could another generic company challenge the same ACZONE patents?

Yes. A separate ANDA applicant could bring its own Paragraph IV challenge, although the outcome could be affected by later settlements, patent expiration, claim amendments, or prior court rulings.

Is ACZONE subject to a biosimilar pathway?

No. ACZONE is a small-molecule topical drug. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

References

1. U.S. District Court for the District of New Jersey. (2020). Bausch Health US, LLC v. Aleor Dermaceuticals Ltd., No. 3:20-cv-02735, docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-content-and-format-anda-submissions